Tenaya Therapeutics Inc (TNYA) Actualités

Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a...

Form 3 - Initial statement of beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Funding will Support Ongoing RIDGE™-1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing...

Form 8-K - Current report

Form 8-K - Current report